India's exports of active pharma ingredients at Rs 41,500 cr surpassed imports in FY25
Analysis of this story by et_economy · 10 Mar 2026, 5:14 PM IST (about 2 months ago)
AI Analysis
The pharmaceutical sector is strategically important for India. Reducing import dependence for APIs enhances supply chain security and boosts domestic manufacturing capabilities.
Trading Insight
Long-term bullish on Indian API manufacturers, especially those participating in the PLI scheme.
Quick check: GRANULES bullish bias (+4.0% 1d), SUNPHARMA bullish bias (overbought).
Key Evidence
- •India's API exports reached Rs 41,500 crore in FY25, surpassing imports of Rs 39,215 crore.
- •The government's Production Linked Incentive (PLI) scheme is aimed at cutting down import dependence, especially from China.
- •Risk flag: Global competition in API manufacturing
- •Risk flag: Quality control issues
- •Risk flag: Changes in government policy
Affected Stocks
GRANULESGranules India Ltd
Positive
As an API producer, it stands to gain from the favorable policy environment and export growth.
Sectors:pharma
Sources and updates
Original source: et_economy
Published: 10 Mar 2026, 5:14 PM IST
Last updated on Anadi News: 10 Mar 2026, 7:46 PM IST
AI-powered analysis by
Anadi Algo News